Margaret Karow, Amgen, to Present at Antibody & Protein Therapeutics Mtg., Oct. 24-25, San Diego
San Diego, CA, August 18, 2013 --(PR.com
)-- Margaret Karow, Executive Director of Biologics Optimization at Amgen, will give a featured presentation titled “Evolution of Antibody Engineering and Assessment” at GTC’s Antibody & Protein Therapeutics Conference on October 24–25, 2013 in San Diego, CA.
The antibody therapeutic field has matured, and through this maturation we have developed higher standards for what is considered a successful antibody therapeutic. In the past, the industry highly depended on process development and formulation science to make antibodies more therapeutic-like. With increased pipeline and efficiency demands, as well as increasing market demands for high concentration formulations, finding the truly therapeutic antibody with efficiency is important for our industry’s success. Utilizing Amgen’s knowledge base from engineering, process development, and manufacturing of many therapeutic antibodies, Dr. Karow’s lab has built a platform for upfront engineering of antibody candidates combined with molecule assessment with the goal of decreasing the iterative rounds of issue-reactive engineering and facilitating rapid progression of molecules into production. This presentation will describe the history and current state of their molecule engineering and assessment process at Amgen.
Margaret Karow, Ph.D, joined Amgen in 2006 as an Executive Director of Protein Sciences and is currently leading the Biologics Optimization organization. In this role, she is responsible for a team of 60 members who engineer antibody and protein lead molecules and assess them to ensure they have the qualities of successful protein therapeutics.
The Antibody & Protein Therapeutics Conference strives to connect representatives from big pharma, academic institutions and government research labs to present data and case studies on key topics such as antibody drug conjugates, bispecific antibodies and overcoming the blood-brain barrier. Attend to learn and network with key opinion leaders in a highly interactive and intimate environment.
For more information, please visit www.gtcbio.com/antibodyprotein